Taigen Biopharmaceuticals Holdings Ltd - Asset Resilience Ratio
Taigen Biopharmaceuticals Holdings Ltd (4157) has an Asset Resilience Ratio of 71.71% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Taigen Biopharmaceuticals Holdings Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Taigen Biopharmaceuticals Holdings Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Taigen Biopharmaceuticals Holdings Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Taigen Biopharmaceuticals Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 4157 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$760.16 Million | 71.71% |
| Total Liquid Assets | NT$760.16 Million | 71.71% |
Asset Resilience Insights
- Very High Liquidity: Taigen Biopharmaceuticals Holdings Ltd maintains exceptional liquid asset reserves at 71.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Taigen Biopharmaceuticals Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Taigen Biopharmaceuticals Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 75.44% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
CureVac NV
F:5CV |
Biotechnology | 0.27% |
|
Replimune Group Inc
NASDAQ:REPL |
Biotechnology | 43.82% |
Annual Asset Resilience Ratio for Taigen Biopharmaceuticals Holdings Ltd (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Taigen Biopharmaceuticals Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.53% | NT$881.66 Million ≈ $27.78 Million |
NT$1.17 Billion ≈ $36.77 Million |
-5.00pp |
| 2024-12-31 | 80.53% | NT$945.68 Million ≈ $29.79 Million |
NT$1.17 Billion ≈ $37.00 Million |
+26.60pp |
| 2023-12-31 | 53.94% | NT$663.34 Million ≈ $20.90 Million |
NT$1.23 Billion ≈ $38.75 Million |
-8.76pp |
| 2022-12-31 | 62.69% | NT$656.39 Million ≈ $20.68 Million |
NT$1.05 Billion ≈ $32.99 Million |
+22.52pp |
| 2021-12-31 | 40.17% | NT$559.46 Million ≈ $17.63 Million |
NT$1.39 Billion ≈ $43.88 Million |
-8.34pp |
| 2020-12-31 | 48.51% | NT$269.92 Million ≈ $8.50 Million |
NT$556.45 Million ≈ $17.53 Million |
-6.07pp |
| 2019-12-31 | 54.57% | NT$516.33 Million ≈ $16.27 Million |
NT$946.11 Million ≈ $29.81 Million |
+1.17pp |
| 2018-12-31 | 53.40% | NT$634.27 Million ≈ $19.98 Million |
NT$1.19 Billion ≈ $37.42 Million |
-3.22pp |
| 2017-12-31 | 56.62% | NT$861.84 Million ≈ $27.15 Million |
NT$1.52 Billion ≈ $47.96 Million |
-8.75pp |
| 2016-12-31 | 65.37% | NT$538.32 Million ≈ $16.96 Million |
NT$823.45 Million ≈ $25.94 Million |
+2.70pp |
| 2015-12-31 | 62.67% | NT$391.97 Million ≈ $12.35 Million |
NT$625.46 Million ≈ $19.71 Million |
-17.61pp |
| 2014-12-31 | 80.28% | NT$881.62 Million ≈ $27.78 Million |
NT$1.10 Billion ≈ $34.60 Million |
+65.56pp |
| 2013-12-31 | 14.72% | NT$71.61 Million ≈ $2.26 Million |
NT$486.49 Million ≈ $15.33 Million |
+4.87pp |
| 2012-12-31 | 9.85% | NT$72.31 Million ≈ $2.28 Million |
NT$733.95 Million ≈ $23.12 Million |
-- |
About Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more